Literature DB >> 27694172

Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis.

Francesco Ceci1, Paolo Castellucci2, Paola Mapelli3, Elena Incerti3, Maria Picchio3, Stefano Fanti1.   

Abstract

The aim of this review is to report on the value of 11C-choline PET imaging as a diagnostic procedure for metastasis-directed therapies. Furthermore, the role of 11C-choline PET/CT as a diagnostic tool for monitoring castration-resistant prostate cancer patients treated with systematic therapy is assessed. Finally, the role of 11C-choline PET/CT in the prediction of survival in both castration-resistant prostate cancer patients and hormone-naïve patients is investigated.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  11C-choline PET/CT; PET-guided therapies; metastasis-directed therapies; salvage lymph node dissection; salvage radiotherapy

Mesh：

Substances：

Year:  2016        PMID： 27694172     DOI： 10.2967/jnumed.115.170126

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  7 in total

1.  11C-Choline Pharmacokinetics in Recurrent Prostate Cancer.

Authors:  Milan Grkovski; Karem Gharzeddine; Peter Sawan; Heiko Schöder; Laure Michaud; Wolfgang A Weber; John L Humm
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

Review 2.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

Review 3.  Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  PET Clin       Date:  2022-05-31

4.  Repeatability of quantitative parameters of 18F-fluoride PET/CT and biochemical tumour and specific bone remodelling markers in prostate cancer bone metastases.

Authors:  Cecilia Wassberg; Mark Lubberink; Jens Sörensen; Silvia Johansson
Journal:  EJNMMI Res       Date:  2017-05-15       Impact factor: 3.138

Review 5.  Current status of theranostics in prostate cancer.

Authors:  Irene Virgolini; Clemens Decristoforo; Alexander Haug; Stefano Fanti; Christian Uprimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-28       Impact factor: 9.236

6.  Effect of positive carbon-11-choline PET/CT results in the therapeutic management of prostate cancer biochemical relapse.

Authors:  Francisco J Gómez-de la Fuente; Isabel Martínez-Rodríguez; Maria De Arcocha-Torres; Remedios Quirce; Julio Jiménez-Bonilla; Néstor Martínez-Amador; Aida Sánchez-Salmón; Blanca Lucas-Velázquez; Oriana Cuenca-Vera; Ignacio Banzo
Journal:  Nucl Med Commun       Date:  2019-01       Impact factor: 1.690

7.  Deep learning-based quantification of PET/CT prostate gland uptake: association with overall survival.

Authors:  Eirini Polymeri; May Sadik; Reza Kaboteh; Pablo Borrelli; Olof Enqvist; Johannes Ulén; Mattias Ohlsson; Elin Trägårdh; Mads H Poulsen; Jane A Simonsen; Poul Flemming Hoilund-Carlsen; Åse A Johnsson; Lars Edenbrandt
Journal:  Clin Physiol Funct Imaging       Date:  2019-12-20       Impact factor: 2.273
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.